Natera, Inc. Common Stock

NTRA · Medical Laboratories · $53.2B
Powering up
NTRA
$369.39
▲ +0.84%
09/18 O 365.78 H 369.69 L 358.90 C 369.39 ▲ +0.84%
Vol 3.7M RS 94
RS rating94
Now vs pivot (%)+28.24%
Tightening (ATR ratio)0.93×
Volume dry-up1.09×
Up/down volume, net0.14
From 52-week high0%
climbing
Previous breakout still open ▲ +42.09% in Jun
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

The read

The base has run 4.8 weeks and fell 14% from its ceiling at its deepest. The pivot is $288.04, and the stock closed 28.2% above that pivot. Its relative strength rating is 94.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap
  1. Earningstentativein 48d
    Quarterly earnings
    Nov 5, 2026
Flagged by the market sweep
Several insiders soldInsider · 2026-09-18
5 insiders sold $62,970,041
GappedTape · 2026-09-18
+6.1%
Several insiders soldInsider · 2026-09-17
4 insiders sold $59,753,897

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Natera, Inc. Common Stock (NTRA) — The Tape